{"id":109668,"date":"2026-06-15T19:20:02","date_gmt":"2026-06-15T19:20:02","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/"},"modified":"2026-06-15T19:20:02","modified_gmt":"2026-06-15T19:20:02","slug":"confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/","title":{"rendered":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<ul>\n<li style=\"margin-top:0in; margin-bottom:0in; text-align:justify;\">Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development<\/li>\n<\/ul>\n<p align=\"justify\"><b>Ghent, Belgium \u2013 June 15, 2026 \u2013 <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=91c-jsKYNjtQPz9_MhokOJKhtj7Ow7a7jLIWURwHHVk2UG2S7V6Q6EVovbv_yta4ZSAiunPhAXwvBqfYRZVpJ19DajRmBo0h0bwcU0tzw54MAOSE9wEakZQ2LSmJWg-N\" rel=\"nofollow\" target=\"_blank\" title=\"Confo Therapeutics\">Confo Therapeutics<\/a>, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the Endocrine Society\u2019s Annual Meeting (ENDO) 2026. The data support CFTX-2034 as a potential first-in-class therapy for PBH, a serious metabolic disorder for which there are currently no approved therapies.<\/p>\n<p>CFTX-2034 is a long-acting, highly selective agonistic antibody designed to target somatostatin receptor subtype 5 (SSTR5), a key regulator of insulin and incretin secretion. Confo is developing CFTX-2034 to restore glycemic control and reduce hypoglycemic episodes associated with PBH, a complication of bariatric surgery that can significantly impair patient independence and quality of life.<\/p>\n<p>Christel Menet, Ph.D., Chief Scientific Officer of Confo Therapeutics, presented the findings at ENDO, held from June 13 &#8211; 16, 2026, in Chicago, Illinois, USA.<\/p>\n<p><strong>T<\/strong><b>he preclinical findings demonstrate that CFTX-2034:<\/b><\/p>\n<ul>\n<li style=\"text-align:left;\">suppressed insulin and GLP-1 secretion in a dose-dependent manner, resulting in improved glycemic control without significantly inducing basal hyperglycemia<\/li>\n<li style=\"text-align:left;\">did not activate related SSTR family members, supporting a selective pharmacology profile<\/li>\n<li style=\"text-align:left;\">possesses a long half-life, establishing the potential for once-monthly subcutaneous administration<\/li>\n<\/ul>\n<p align=\"justify\">\u201cTo our knowledge, Confo is the only company advancing a therapeutic candidate for PBH that targets SSTR5, a well-validated driver of disease biology,\u201d said Dr. Christel Menet, CSO of Confo Therapeutics. \u201cImportantly, leading clinical experts see the strong potential of CFTX-2034 to offer much needed glycemic control in PBH. In addition, CFTX-2034 is potentially compatible with GLP-1 agonists that are used by many patients for additional post-surgery weight management.\u201d<\/p>\n<p>\u201cCFTX-2034 reflects our team\u2019s ability to once again rapidly translate deep GPCR expertise into a high-quality therapeutic candidate,\u201d added Cedric Ververken, CEO of Confo Therapeutics. \u201cThe data presented at ENDO 2026 support continued advancement of CFTX-2034 through IND-enabling studies and reinforce the strength of our pipeline in endocrine and metabolic diseases.\u201d<\/p>\n<p><b>About Post-Bariatric Hypoglycemia (PBH)<\/b><\/p>\n<p>Post-bariatric hypoglycemia (PBH) is a serious metabolic condition that has no approved treatments. It can develop after weight loss surgery and is characterized by dangerously low blood sugar levels following food intake. PBH can cause hypoglycemic events which can be debilitating and manifest as impaired cognition, loss of consciousness, and even seizures. PBH can result in major disruptions to the quality of life and the independence of patients.<\/p>\n<p><b>About Confo Therapeutics<\/b><\/p>\n<p>Confo Therapeutics is a clinical-stage biotechnology company committed to identifying and accelerating novel medicines targeting GPCRs (G protein-coupled receptors). It discovers small molecules and antibodies with the desired pharmacology by employing its proprietary discovery platform which uses conformation-specific ConfoBodies\u00ae to promote GPCRs into functionally relevant states. Using its platform, the company is building a pipeline of product candidates to transform therapeutic outcomes for patients with a focus on metabolic and endocrine diseases. The Company\u2019s mission is being advanced by a team of highly experienced industry experts with extensive knowledge of the discovery and development of GPCR-directed medicines. Confo Therapeutics is headquartered in Ghent, Belgium. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pc-OXjvD-Ifj-OzJKoZy4B9yvesf2zz8ki0666_WgJaPnv6_8RhXcfZn232VLAkB26AW7MJREyr8zAJEDup48GuNys1_C30wwDN_vfQ7_S0iIbuDVMNASWoKV6sFtN3v\" rel=\"nofollow\" target=\"_blank\" title=\"www.confotherapeutics.com\">www.confotherapeutics.com<\/a><\/p>\n<p><b>For more information, please contact:<\/b><\/p>\n<p><b>Confo Therapeutics<br \/><\/b>Dr. Cedric Ververken, CEO<br \/>+32 (0) 9 396 74 00<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=60xjXd8TfCG3rOYXrIFStK-Y8_7iaKqIqtwVyqxoCrfOUdzCGG5YfsU3R-avR_UMZwPbFdtKS3fXnPh--N-pK33fokymXYy81HgyQuCo93qwmzspmkRDduGAzqitg8Hs\" rel=\"nofollow\" target=\"_blank\" title=\"info@confotherapeutics.com\">info@confotherapeutics.com<\/a><\/p>\n<p><b>Trophic Communications<br \/><\/b>Valeria Fisher \/ Adolfo Luna<br \/>+49 (0) 175 8041816 \/ +49 (0) 151 62674395<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g6tCoUBPaojt_wGlsHCJxQJosDicSslSjbs-6eTtgKVcSgU3QdLXPj5c9wp9CpUGzuZyb4Kft7siNdehgg2NORRPRdLrCHNyGqoanoJ0RWM=\" rel=\"nofollow\" target=\"_blank\" title=\"confo@trophic.eu\">confo@trophic.eu<\/a><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=ACW7eyT_v-IwRQafQOqkxR53R1Fpn21BkAGpX-pGSMbcufAEX7OYAKUq3hgBz58DWoqVJblbYfOI8A7LjGQi7CleMDNwO9tEA7xNabFE2Db3PDbBos_llXUA5XBuGzofm07J4XiBOChIAaYI1Jj9gFfA59SuhI_zu0gECRK-pJ-dkkdH7Arx1PFf10wEQjxhodsXGmKf-BnwzwrQ19Wb9daaRibEkeII7XzOyN1Z8E1bBB1lHjYBpA-7zzxjHP7qvdQ-tOBj7eOpk_aQLmhfyi48jAv4zcUq5-ZkfTmHFP0cfnYSvQlZjYjeGv27NI6x\" title=\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\" rel=\"nofollow\">Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026<\/a>\n      <\/li>\n<\/ul>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":109669,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/a9fcac03-0dcc-4a7b-b073-1b8fe4c6cf72","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-109668","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Gias Ul Hassan\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan - Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\" \/>\n\t\t<meta property=\"og:description\" content=\"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-06-15T19:20:02+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-06-15T19:20:02+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#blogposting\",\"name\":\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\",\"headline\":\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\",\"author\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml-eu.globenewswire.com\\\/Resource\\\/Download\\\/a9fcac03-0dcc-4a7b-b073-1b8fe4c6cf72\"},\"datePublished\":\"2026-06-15T19:20:02+00:00\",\"dateModified\":\"2026-06-15T19:20:02+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#webpage\"},\"articleSection\":\"GlobeNewswire\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewswire\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"position\":2,\"name\":\"GlobeNewswire\",\"item\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#listItem\",\"name\":\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#listItem\",\"position\":3,\"name\":\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewswire\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\",\"name\":\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan\",\"description\":\"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/Pakistan-News.png\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#organizationLogo\",\"width\":191,\"height\":78,\"caption\":\"Pakistan-News\"},\"image\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/\",\"name\":\"Gias Ul Hassan\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#webpage\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/\",\"name\":\"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\",\"description\":\"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \\u2013 June 15, 2026 \\u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml-eu.globenewswire.com\\\/Resource\\\/Download\\\/a9fcac03-0dcc-4a7b-b073-1b8fe4c6cf72\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#mainImage\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\\\/#mainImage\"},\"datePublished\":\"2026-06-15T19:20:02+00:00\",\"dateModified\":\"2026-06-15T19:20:02+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#website\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/\",\"name\":\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan\",\"description\":\"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","description":"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the","canonical_url":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#blogposting","name":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","headline":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","author":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"publisher":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/a9fcac03-0dcc-4a7b-b073-1b8fe4c6cf72"},"datePublished":"2026-06-15T19:20:02+00:00","dateModified":"2026-06-15T19:20:02+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#webpage"},"isPartOf":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#webpage"},"articleSection":"GlobeNewswire"},{"@type":"BreadcrumbList","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news#listItem","position":1,"name":"Home","item":"https:\/\/pakistaninewspaperlist.com\/news","nextItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewswire"}},{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","position":2,"name":"GlobeNewswire","item":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/","nextItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#listItem","name":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026"},"previousItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#listItem","position":3,"name":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","previousItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewswire"}}]},{"@type":"Organization","@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization","name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan","description":"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","url":"https:\/\/pakistaninewspaperlist.com\/news\/","logo":{"@type":"ImageObject","url":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#organizationLogo","width":191,"height":78,"caption":"Pakistan-News"},"image":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author","url":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/","name":"Gias Ul Hassan"},{"@type":"WebPage","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#webpage","url":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/","name":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","description":"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#website"},"breadcrumb":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#breadcrumblist"},"author":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"creator":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/a9fcac03-0dcc-4a7b-b073-1b8fe4c6cf72","@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#mainImage"},"primaryImageOfPage":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/#mainImage"},"datePublished":"2026-06-15T19:20:02+00:00","dateModified":"2026-06-15T19:20:02+00:00"},{"@type":"WebSite","@id":"https:\/\/pakistaninewspaperlist.com\/news\/#website","url":"https:\/\/pakistaninewspaperlist.com\/news\/","name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan","description":"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","inLanguage":"en-US","publisher":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization"}}]},"og:locale":"en_US","og:site_name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan - Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","og:type":"article","og:title":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","og:description":"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the","og:url":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/","og:image":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","og:image:secure_url":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","article:published_time":"2026-06-15T19:20:02+00:00","article:modified_time":"2026-06-15T19:20:02+00:00","twitter:card":"summary_large_image","twitter:title":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","twitter:description":"Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium \u2013 June 15, 2026 \u2013 Confo Therapeutics, a clinical-stage biotechnology company advancing novel GPCR-directed medicines, today announced preclinical data for CFTX-2034, its SSTR5 agonistic antibody for the treatment of post-bariatric hypoglycemia (PBH), at the","twitter:image":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png"},"aioseo_meta_data":{"post_id":"109668","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2026-06-16 02:22:02","updated":"2026-06-16 02:22:02","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/pakistaninewspaperlist.com\/news\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/\" title=\"GlobeNewswire\">GlobeNewswire<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tConfo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/pakistaninewspaperlist.com\/news"},{"label":"GlobeNewswire","link":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/"},{"label":"Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026","link":"https:\/\/pakistaninewspaperlist.com\/news\/confo-therapeutics-announces-encouraging-preclinical-data-for-post-bariatric-hypoglycemia-candidate-cftx-2034-at-endo-2026\/"}],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/109668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=109668"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/109668\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/109669"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=109668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=109668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=109668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}